SENTI BIOSCIENCES INC (SNTI) Fundamental Analysis & Valuation

NASDAQ:SNTI • US81726A2096

0.9508 USD
+0.02 (+2.14%)
At close: Mar 3, 2026
0.9381 USD
-0.01 (-1.34%)
After Hours: 3/3/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SNTI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall SNTI gets a fundamental rating of 2 out of 10. We evaluated SNTI against 520 industry peers in the Biotechnology industry. The financial health of SNTI is average, but there are quite some concerns on its profitability. SNTI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. SNTI Profitability Analysis

1.1 Basic Checks

  • In the past year SNTI has reported negative net income.
  • SNTI had a negative operating cash flow in the past year.
  • In the past 5 years SNTI always reported negative net income.
  • In the past 5 years SNTI always reported negative operating cash flow.
SNTI Yearly Net Income VS EBIT VS OCF VS FCFSNTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -90.31%, SNTI is doing worse than 72.69% of the companies in the same industry.
  • SNTI has a worse Return On Equity (-585.90%) than 76.73% of its industry peers.
Industry RankSector Rank
ROA -90.31%
ROE -585.9%
ROIC N/A
ROA(3y)-48.54%
ROA(5y)-48.78%
ROE(3y)-85.31%
ROE(5y)-82.35%
ROIC(3y)N/A
ROIC(5y)N/A
SNTI Yearly ROA, ROE, ROICSNTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SNTI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNTI Yearly Profit, Operating, Gross MarginsSNTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. SNTI Health Analysis

2.1 Basic Checks

  • SNTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SNTI has more shares outstanding than it did 1 year ago.
  • SNTI has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for SNTI is higher compared to a year ago.
SNTI Yearly Shares OutstandingSNTI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
SNTI Yearly Total Debt VS Total AssetsSNTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -12.82, we must say that SNTI is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -12.82, SNTI is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
  • SNTI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.82
ROIC/WACCN/A
WACC8.68%
SNTI Yearly LT Debt VS Equity VS FCFSNTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • SNTI has a Current Ratio of 1.51. This is a normal value and indicates that SNTI is financially healthy and should not expect problems in meeting its short term obligations.
  • SNTI's Current ratio of 1.51 is on the low side compared to the rest of the industry. SNTI is outperformed by 81.73% of its industry peers.
  • A Quick Ratio of 1.51 indicates that SNTI should not have too much problems paying its short term obligations.
  • SNTI's Quick ratio of 1.51 is on the low side compared to the rest of the industry. SNTI is outperformed by 80.38% of its industry peers.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 1.51
SNTI Yearly Current Assets VS Current LiabilitesSNTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. SNTI Growth Analysis

3.1 Past

  • SNTI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.10%, which is quite impressive.
  • The Revenue for SNTI has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)82.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.06%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • SNTI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.52% yearly.
  • Based on estimates for the next years, SNTI will show a very strong growth in Revenue. The Revenue will grow by 73.65% on average per year.
EPS Next Y81.81%
EPS Next 2Y37.96%
EPS Next 3Y23.63%
EPS Next 5Y13.52%
Revenue Next Year-76.19%
Revenue Next 2Y-22.85%
Revenue Next 3Y-25.99%
Revenue Next 5Y73.65%

3.3 Evolution

SNTI Yearly Revenue VS EstimatesSNTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 2031 2032 2033 100M 200M 300M
SNTI Yearly EPS VS EstimatesSNTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

1

4. SNTI Valuation Analysis

4.1 Price/Earnings Ratio

  • SNTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SNTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNTI Price Earnings VS Forward Price EarningsSNTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNTI Per share dataSNTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SNTI's earnings are expected to grow with 23.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.96%
EPS Next 3Y23.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SNTI Dividend Analysis

5.1 Amount

  • SNTI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SNTI Fundamentals: All Metrics, Ratios and Statistics

SENTI BIOSCIENCES INC

NASDAQ:SNTI (3/3/2026, 8:00:02 PM)

After market: 0.9381 -0.01 (-1.34%)

0.9508

+0.02 (+2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-18
Inst Owners22.3%
Inst Owner Change-4.25%
Ins Owners0.85%
Ins Owner Change-0.02%
Market Cap25.00M
Revenue(TTM)N/A
Net Income(TTM)-47.58M
Analysts84
Price Target11.73 (1133.7%)
Short Float %7.36%
Short Ratio2.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.81%
Min EPS beat(2)-19.38%
Max EPS beat(2)39%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.17%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.08
P/tB 3.08
EV/EBITDA N/A
EPS(TTM)-2.79
EYN/A
EPS(NY)-1.44
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.9
OCFYN/A
SpS0
BVpS0.31
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -90.31%
ROE -585.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.54%
ROA(5y)-48.78%
ROE(3y)-85.31%
ROE(5y)-82.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.62%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.51
Quick Ratio 1.51
Altman-Z -12.82
F-Score4
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)1099.41%
Cap/Depr(5y)844.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.06%
EPS Next Y81.81%
EPS Next 2Y37.96%
EPS Next 3Y23.63%
EPS Next 5Y13.52%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-76.19%
Revenue Next 2Y-22.85%
Revenue Next 3Y-25.99%
Revenue Next 5Y73.65%
EBIT growth 1Y-5.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.89%
OCF growth 3YN/A
OCF growth 5YN/A

SENTI BIOSCIENCES INC / SNTI FAQ

What is the ChartMill fundamental rating of SENTI BIOSCIENCES INC (SNTI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SNTI.


What is the valuation status for SNTI stock?

ChartMill assigns a valuation rating of 1 / 10 to SENTI BIOSCIENCES INC (SNTI). This can be considered as Overvalued.


Can you provide the profitability details for SENTI BIOSCIENCES INC?

SENTI BIOSCIENCES INC (SNTI) has a profitability rating of 0 / 10.


How financially healthy is SENTI BIOSCIENCES INC?

The financial health rating of SENTI BIOSCIENCES INC (SNTI) is 4 / 10.